Sign in or Register   Sign in or Register
  |  

Mouse Anti-C3 Recombinant Antibody (4C6A8) (CBMAB-C6739-LY)

This product is antibody recognizes C3. The antibody 4C6A8 immunoassay techniques such as: ELISA, WB, IHC-P, IF/IHC-F, FC.
See all C3 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
4C6A8
Antibody Isotype
IgG1
Application
ELISA, WB, IHC-P, IF/IHC-F, FC

Basic Information

Immunogen
Recombinant fragment of human C3C (AA: 1521-1649) expressed in E. Coli
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Preservative
0.05% sodium azide
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
C3
Entrez Gene ID
UniProt ID
Function
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity).
It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
C3-beta-c: Acts as a chemoattractant for neutrophils in chronic inflammation.
Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).
Biological Process
Amyloid-beta clearance Source: ARUK-UCL
Cell surface receptor signaling pathway involved in cell-cell signaling Source: Ensembl
Cellular protein metabolic process Source: Reactome
Complement activation Source: BHF-UCL
Complement activation, alternative pathway Source: Reactome
Complement activation, classical pathway Source: UniProtKB-KW
Complement-dependent cytotoxicity Source: Ensembl
Complement-mediated synapse pruning Source: ARUK-UCL
Fatty acid metabolic process Source: UniProtKB-KW
G protein-coupled receptor signaling pathway Source: Reactome
Immune response Source: ProtInc
Inflammatory response Source: UniProtKB-KW
Neuron remodeling Source: ARUK-UCL
Neutrophil degranulation Source: Reactome
Oviduct epithelium development Source: Ensembl
Positive regulation of activation of membrane attack complex Source: Ensembl
Positive regulation of angiogenesis Source: Ensembl
Positive regulation of apoptotic cell clearance Source: BHF-UCL
Positive regulation of glucose transmembrane transport Source: UniProtKB
Positive regulation of G protein-coupled receptor signaling pathway Source: UniProtKB
Positive regulation of lipid storage Source: UniProtKB
Positive regulation of phagocytosis, engulfment Source: ARUK-UCL
Positive regulation of protein phosphorylation Source: UniProtKB
Positive regulation of receptor-mediated endocytosis Source: ARUK-UCL
Positive regulation of type IIa hypersensitivity Source: Ensembl
Positive regulation of vascular endothelial growth factor production Source: BHF-UCL
Post-translational protein modification Source: Reactome
Purinergic nucleotide receptor signaling pathway Source: Reactome
Regulation of complement activation Source: Reactome
Regulation of immune response Source: Reactome
Regulation of triglyceride biosynthetic process Source: UniProtKB
Response to bacterium Source: Ensembl
Signal transduction Source: ProtInc
Vertebrate eye-specific patterning Source: ARUK-UCL
Cellular Location
Secreted
Involvement in disease
Complement component 3 deficiency (C3D): A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
Macular degeneration, age-related, 9 (ARMD9): A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Hemolytic uremic syndrome atypical 5 (AHUS5): An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease.
Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage.
PTM
C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g. C3a is further processed by carboxypeptidases to release the C-terminal arginine residue generating the acylation stimulating protein (ASP). Levels of ASP are increased in adipocytes in the postprandial period and by insulin and dietary chylomicrons.
(Microbial infection) C3 is cleaved by Staphylococcus aureus aureolysin; this cleavage renders C3a and C3b inactive. C3b is rapidly degraded by host factors CFH and CFI preventing its deposition on the bacterial surface while C3a is further inactivated by aureolysin.
Phosphorylated by FAM20C in the extracellular medium.

Yuan, K., Ye, J., Liu, Z., Ren, Y., He, W., Xu, J., ... & Yuan, Y. (2020). Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression. Journal of Experimental & Clinical Cancer Research, 39(1), 1-15.

Mastaglio, S., Ruggeri, A., Risitano, A. M., Angelillo, P., Yancopoulou, D., Mastellos, D. C., ... & Ciceri, F. (2020). The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clinical Immunology, 215, 108450.

Mastellos, D. C., da Silva, B. G. P., Fonseca, B. A., Fonseca, N. P., Auxiliadora-Martins, M., Mastaglio, S., ... & Lambris, J. D. (2020). Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical Immunology, 220, 108598.

Liao, D. S., Grossi, F. V., El Mehdi, D., Gerber, M. R., Brown, D. M., Heier, J. S., ... & Francois, C. G. (2020). Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology, 127(2), 186-195.

Zhang, L. Y., Pan, J., Mamtilahun, M., Zhu, Y., Wang, L., Venkatesh, A., ... & Yang, G. Y. (2020). Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion. Theranostics, 10(1), 74.

Wu, T., Dejanovic, B., Gandham, V. D., Gogineni, A., Edmonds, R., Schauer, S., ... & Hanson, J. E. (2019). Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell reports, 28(8), 2111-2123.

Bosco, A., Anderson, S. R., Breen, K. T., Romero, C. O., Steele, M. R., Chiodo, V. A., ... & Vetter, M. L. (2018). Complement C3-targeted gene therapy restricts onset and progression of neurodegeneration in chronic mouse glaucoma. Molecular Therapy, 26(10), 2379-2396.

Sorbara, M. T., Foerster, E. G., Tsalikis, J., Abdel-Nour, M., Mangiapane, J., Sirluck-Schroeder, I., ... & Philpott, D. J. (2018). Complement C3 drives autophagy-dependent restriction of cyto-invasive bacteria. Cell host & microbe, 23(5), 644-652.

Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., ... & Lemere, C. A. (2017). Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Science translational medicine, 9(392).

Mastellos, D. C., Reis, E. S., Ricklin, D., Smith, R. J., & Lambris, J. D. (2017). Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery. Trends in immunology, 38(6), 383-394.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-C3 Recombinant Antibody (4C6A8)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare